Literature DB >> 19252404

Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.

Qian Cao1, Qin Zhu, Yan Shang, Min Gao, Jianmin Si.   

Abstract

BACKGROUND: The thiopurine drugs azathioprine and 6-mercaptopurine are well established in the treatment of inflammatory bowel disease (IBD). However, great interpatient variability exists in the efficacy and toxicity of the drugs, and this results from thiopurine methyltransferase (TPMT) gene polymorphisms. The aim of this study was to identify the TPMT gene polymorphisms in Chinese IBD patients and to study the relationship between TPMT status and thiopurine-related toxicity in these patients.
MATERIALS AND METHODS: A total of 189 IBD patients, 87 with Crohn's disease and 102 with ulcerative colitis, and 273 healthy controls were enrolled. All subjects were from the Han Chinese ethnic group. Polymorphisms in TPMT*2, *3A, *3B and *3C were analyzed using allele-specific polymerase chain reaction and polymerase chain reaction-restriction fragment length polymorphism. Direct sequencing was used to confirm the mutation results. Exons of the TPMT gene from patients who suffered from azathioprine-induced toxicity were amplified and sequenced to detect TPMT mutations.
RESULTS: No TPMT*2, *3A or *3B mutant alleles were detected. The allele frequency of TPMT*3C in the IBD group was 1.59%, which was similar to that of the healthy control group (1.59 vs. 1.47%, p = 1.000). Forty-three patients were treated with azathioprine therapy, 4 experienced myelotoxicity, and 1 experienced hepatotoxicity, so the incidence of drug toxicity was 11.7% (5/43). No TPMT*2, *3A, *3B or *3C polymorphisms were detected in these 5 patients. After directly sequencing the exons of the TPMT gene in these 5 patients, a synonymous single-nucleotide polymorphism (TPMT*1S), which does not alter the encoded amino acid, was found in 3 patients.
CONCLUSION: TPMT*3C seemed to be a unique variant allele in this Han Chinese population. The overall frequencies of variant TPMT alleles in this population were lower than those in Caucasians, but thiopurine toxicity in Han Chinese IBD patients is not low. Factors other than TPMT polymorphisms may be responsible for the development of toxicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19252404     DOI: 10.1159/000205268

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  19 in total

Review 1.  The role of pharmacogenetics in nonmalignant gastrointestinal diseases.

Authors:  Michael Camilleri
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-07       Impact factor: 46.802

Review 2.  Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease.

Authors:  Xian-Wen Dong; Qing Zheng; Ming-Ming Zhu; Jing-Lu Tong; Zhi-Hua Ran
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

3.  A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia.

Authors:  Suk-Kyun Yang; Myunghee Hong; Jiwon Baek; Hyunchul Choi; Wanting Zhao; Yusun Jung; Talin Haritunians; Byong Duk Ye; Kyung-Jo Kim; Sang Hyoung Park; Soo-Kyung Park; Dong-Hoon Yang; Marla Dubinsky; Inchul Lee; Dermot P B McGovern; Jianjun Liu; Kyuyoung Song
Journal:  Nat Genet       Date:  2014-08-10       Impact factor: 38.330

4.  Thiopurine-methyltransferase variants in inflammatory bowel disease: prevalence and toxicity in Brazilian patients.

Authors:  Ana Teresa P Carvalho; Barbara C Esberard; Renata S B Fróes; Davy C M Rapozo; Ana B Grinman; Tatiana A Simão; Juliana C V C Santos; Antonio José V Carneiro; Luis Felipe Ribeiro-Pinto; Heitor S P de Souza
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

Review 5.  The Same Intestinal Inflammatory Disease despite Different Genetic Risk Factors in the East and West?

Authors:  Rashid N S Lui; Siew C Ng
Journal:  Inflamm Intest Dis       Date:  2016-07-15

Review 6.  Precision medicine for rheumatologists: lessons from the pharmacogenomics of azathioprine.

Authors:  Laura L Daniel; Alyson L Dickson; Cecilia P Chung
Journal:  Clin Rheumatol       Date:  2020-07-02       Impact factor: 2.980

7.  The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis.

Authors:  Guiqiang Wang; Atsushi Tanaka; Hong Zhao; Jidong Jia; Xiong Ma; Kenichi Harada; Fu-Sheng Wang; Lai Wei; Qixia Wang; Ying Sun; Yuan Hong; Huiying Rao; Cumali Efe; George Lau; Diana Payawal; Rino Gani; Keith Lindor; Wasim Jafri; Masao Omata; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-05-04       Impact factor: 6.047

8.  Effect of NUDT15 polymorphisms on early hematological safety of low-dose azathioprine in Chinese patients with pemphigus vulgaris: A prospective cohort study.

Authors:  Xingli Zhou; Liangliang Cheng; Yiyi Wang; Hui Gou; Ke Ju; TianJiao Lan; Tongying Zhan; GaoJie Li; Yuanxia Gu; Yeting Sun; Yan Xu; Yukun Sun; Yanhong Zhou; Wei Li
Journal:  J Dermatol       Date:  2021-12-05       Impact factor: 3.468

Review 9.  Monitoring and safety of azathioprine therapy in inflammatory bowel disease.

Authors:  Mi Jin Kim; Yon Ho Choe
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2013-06-30

10.  Adverse events associated with azathioprine treatment in korean pediatric inflammatory bowel disease patients.

Authors:  Ji Young Chun; Ben Kang; Yoo Min Lee; Soo Youn Lee; Mi Jin Kim; Yon Ho Choe
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2013-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.